This test is most useful if any of these apply to you.
An abnormal newborn screen, unexplained episodes of serious illness, or a family history can raise the question of an inherited problem with breaking down protein. Urinary isovalerylglycine helps investigate that question. It forms during the breakdown of leucine, an amino acid in dietary protein, and can accumulate when that process is blocked.
This is an established diagnostic marker for isovaleric acidemia. Its interpretation depends on the pattern of other urine compounds, blood results, and sometimes genetic testing. Researchers are also studying it in kidney disease and obesity, but those uses remain exploratory. A routine urine result hasn't been validated as a general measure of metabolic health or longevity.
Leucine is broken down in a series of steps inside the energy-producing compartments of your cells. One step depends on the enzyme isovaleryl-CoA dehydrogenase, abbreviated IVD. When this enzyme doesn't work properly, isovaleryl-CoA accumulates and can give rise to isovaleric acid and other compounds.
The liver and kidneys can attach glycine to isovaleryl-CoA. Glycine is an amino acid that your body makes and also gets from food. The resulting isovalerylglycine, or IVG, is considered a nontoxic disposal product and leaves the body in urine. Another route produces isovalerylcarnitine, which contributes to the signal used in newborn blood screening.
Urine IVG is measured with methods that separate compounds and identify them by their molecular mass. This technique is called mass spectrometry. Quantitative results are commonly reported relative to urine creatinine to reduce the effect of dilution. IVG can remain elevated between episodes of illness, making it useful even when someone with the disorder feels well.
Isovaleric acidemia, or IVA, results from disease-causing changes in both copies of the IVD gene, usually inherited one from each parent. Severe cases can cause poor feeding, vomiting, unusual sleepiness, a smell often compared to sweaty feet, acid buildup in the blood, high ammonia, and reduced blood cell counts. Some affected people have a much milder form and remain symptom-free.
Initial urine results can help assess severity, but they don't predict an individual child's course precisely. A German study followed children identified through newborn screening into childhood. Among those with numerical urine IVG results, the initial value tended to be considerably higher in children who later had a metabolic crisis than in those who didn't. The groups overlapped substantially.
The same study found that urine results alone could classify some children with mild disease as having a more severe form. Combining the urine pattern with newborn blood screening results, IVD gene findings, and clinical history gave a more useful assessment.
Early detection and treatment improve the outlook for classic IVA. A meta-analysis of observational studies estimated considerably lower mortality and a much lower rate of developmental delay among people identified through newborn screening than among those diagnosed after symptoms appeared. These pooled estimates describe newborn screening followed by care. They don't measure the benefit of urine testing alone.
Screening whole populations of newborns revealed a mild form of IVA that older clinical reports had largely missed. In a German follow-up study, people classified as having mild IVA had excellent developmental outcomes and no metabolic crises during observation, regardless of maintenance treatment. Elevated IVG therefore doesn't automatically mean that severe illness will develop.
Genetics also has limits as a predictor. In a small South African study, people sharing the same disease-causing IVD variant had presentations ranging from severe illness to no symptoms. The urine pattern, genetic findings, and personal history all contribute to understanding the condition.
Newborn blood screening measures a signal called C5 acylcarnitine. Several compounds can contribute to that signal. These include isovalerylcarnitine from IVA, a related compound from a separate disorder of isoleucine breakdown, and pivaloylcarnitine following exposure to certain medicines or skin products.
The urine pattern helps distinguish these possibilities. IVA produces IVG, while the separate condition called 2-methylbutyrylglycinuria produces 2-methylbutyrylglycine. Pivalate exposure can raise the blood screening signal without producing the characteristic urine pattern of IVA. Some screening programs also use additional blood-spot tests to separate these causes.
IVG is most informative as part of that diagnostic pattern. It can also rise in disorders that affect several steps of fat and amino acid breakdown, such as multiple acyl-CoA dehydrogenase deficiency. Those conditions generally produce abnormalities in several urine and blood compounds.
Your kidneys remove IVG through both filtration and active transport into urine. Researchers have studied this second process by comparing urine IVG with its concentration in blood. These measurements differ from the amount reported by a urine-only test.
| Who Was Studied | What Was Measured | What They Found |
|---|---|---|
| Black adults in the Jackson Heart Study, with kidney function reassessed years later | IVG clearance calculated from blood and a 24-hour urine collection | Lower clearance was associated with higher odds of a substantial later decline in estimated kidney filtration. |
| 170 adults in intensive care | The ratio of IVG in a spot urine sample to IVG in blood | A lower ratio was associated with a higher risk of a combined outcome of worsening kidney function, dialysis dependence, or death within 28 days. |
| Adults with diabetes, with and without diabetic foot complications | Urine compounds measured using a research magnetic resonance method | IVG was associated with existing foot complications in an exploratory analysis. This method and study design don't establish how a routine urine IVG result predicts future complications. |
The kidney studies required matched blood measurements. A urine IVG concentration alone cannot reproduce their clearance or urine-to-blood calculations. The diabetic foot study compared people who already had complications with people who didn't; it wasn't a test of whether IVG predicts who will develop them.
A small study found that adults with severe obesity had lower blood glycine, lower urinary IVG, and slower IVG production than healthy-weight participants. This supports the idea that glycine availability can influence how much IVG is formed. It doesn't establish a low urine result as a diagnosis of glycine deficiency, or a higher result as a health target.
A urine result reflects how much IVG is produced, how it is removed, and how concentrated the sample is. Some changes come from collection conditions; others reflect changes in the body that need clinical context.
Serial IVG results can document changes in excretion, but there is no single direction that consistently means better disease control. In established IVA, symptoms, growth, nutritional status, and blood measurements provide the context. During a suspected crisis, blood ammonia, acid-base status, and other urgent assessments guide care; urine IVG is not a substitute.
Evidence-backed interventions that affect your Isovalerylglycine level
Isovalerylglycine is best interpreted alongside these tests.
Isovalerylglycine is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers